Page 112 - ITPS-8-2

INNOSC Theranostics and
Pharmacological Sciences Drug-induced hypoglycemia

management. This case underscores the importance Consent for publication
of individualized treatment plans that account for the
interplay between diabetes and comorbid conditions. A verbal and written formed consent was obtained from
the patient.
3.4. Limitations Availability of data
As a single-patient case report, these results cannot be
generalized to all individuals with similar conditions. Not applicable.
Differences in comorbidities, renal function, and References
pharmacogenetics may affect outcomes, emphasizing the
need for a personalized approach to managing T2DM and 1. International Diabetes Federation. IDF Diabetes Atlas. 9 ed.
th
associated comorbidities. This report contributes to the Brussels, Belgium: International Diabetes Federation; 2019.
understanding of T2DM management in patients with Available from: https://www.diabetesatlas.org [Last accessed
CKD, offering valuable insights into optimizing therapeutic on 2023 May 30].
strategies while minimizing adverse effects. 2. American Diabetes Association. 2. Classification and
diagnosis of diabetes: Standards of medical care in
4. Conclusion diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15-S33.
This case report highlights the complexities of managing doi: 10.2337/dc21-S002
T2DM in patients with renal impairment and comorbidities, 3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of
particularly the heightened risk of hypoglycemia associated hyperglycemia in type 2 diabetes, 2015: A patient-centered
with certain antidiabetic regimens. The recurrent approach: Update to a position statement of the American
hypoglycemic episodes experienced by the patient while diabetes association and the European association for the
taking a combination of glimepiride, metformin, and study of diabetes. Diabetes Care. 2015;38(1):140-149.
voglibose were attributed to altered drug clearance and doi: 10.2337/dc14-2441
pharmacokinetics resulting from renal dysfunction.
Switching to linagliptin, a renal-friendly alternative 4. Li T, Providencia R, Mu N, et al. Association of metformin
antidiabetic agent, resulted in improved glycemic control monotherapy or combined therapy with cardiovascular
risks in patients with type 2 diabetes mellitus. Cardiovasc
and resolution of hypoglycemia. This case emphasizes the Diabetol. 2021;20(1):30.
need to tailor diabetes management to individual patient
needs, with careful consideration of comorbidities, regular doi: 10.1186/s12933-020-01202-5
monitoring of blood glucose levels, and assessment of renal 5. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and
function to prevent adverse outcomes and ensure safe and diabetes: A report of a workgroup of the American Diabetes
effective therapy. Association and the Endocrine Society. Diabetes Care.
2013;36(5):1384-1395.
Acknowledgments doi: 10.2337/dc12-2480

None. 6. Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi, T.
Diabetic kidney disease: World wide difference of prevalence
Funding and risk factors. J Nephropharmacol. 2015;5(1):49-56.
None. 7. De Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS,
Himmelfarb J. Temporal trends in the prevalence of
Conflict of interest diabetic kidney disease in the United States. JAMA.
The authors declare that they have no competing interests. 2011;305(24):2532-2539.
doi: 10.1001/jama.2011.861
Author contributions
8. Getachew H, Tadesse Y, Shibeshi W. Drug dosage adjustment
Conceptualization: All authors in hospitalized patients with renal impairment at Tikur
Investigation: All authors Anbessa specialized hospital, Addis Ababa, Ethiopia. BMC
Writing–original draft: All authors Nephrol. 2015;16:158.
Writing–review & editing: All authors doi: 10.1186/s12882-015-0155-9
Ethics approval and consent to participate 9. Oh TJ, Yu JM, Min KW, et al. Efficacy and safety of
voglibose plus metformin in patients with type 2 diabetes
Verbal and written consent was obtained from the patient mellitus: A randomized controlled trial. Diabetes Metab J.
before his participation. 2019;43(3):276-286.

Volume 8 Issue 2 (2025) 106 doi: 10.36922/itps.7355